Literature DB >> 6204013

Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia.

H Arai, K Kosaka, R Iizuka.   

Abstract

Noradrenaline (NA), 3,4-dihydroxyphenylethylamine (dopamine, DA), 5-hydroxytryptamine (serotonin, 5-HT), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA) were measured in 22 regions of postmortem brains from four histologically verified cases with Alzheimer-type dementia (ATD) and nine histologically normal controls. Compared with the controls, concentrations of 5-HT and 5-HIAA in the ATD brains were significantly reduced in nine regions (superior frontal gyrus, insula, cingulate gyrus, amygdala, putamen, medial and lateral segments of globus pallidus, substantia nigra, lateral nucleus of thalamus) and in eight regions (amygdala, substantia innominata, caudate, putamen, medial and lateral segments of globus pallidus, medial and lateral nuclei of thalamus), respectively. NA concentrations of the ATD brains were significantly reduced in six regions (cingulate gyrus, substantia innominata, putamen, hypothalamus, medial nucleus of thalamus, raphe area). In contrast, significant reductions of DA and HVA concentrations in the ATD brains were found only in putamen and amygdala, respectively. The 5-HIAA/5-HT ratio in the ATD brains decreased significantly in locus coeruleus, while the HVA/DA ratio increased significantly in putamen and medial segment of globus pallidus. These findings suggest that the serotonergic and noradrenergic systems are affected, while the dopaminergic system is relatively unaffected in ATD brains.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204013     DOI: 10.1111/j.1471-4159.1984.tb00913.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  33 in total

1.  Distribution of the beta-2 adrenergic receptor messenger RNA in the rat brain by in situ hybridization histochemistry: effects of chronic reserpine treatment.

Authors:  M Asanuma; N Ogawa; K Mizukawa; K Haba; H Hirata; A Mori
Journal:  Neurochem Res       Date:  1991-12       Impact factor: 3.996

2.  Parvalbumin-immunoreactive neurons in the cortex in Pick's disease.

Authors:  H Arai; I Noguchi; Y Makino; K Kosaka; C W Heizmann; R Iizuka
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

Review 3.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

4.  The basis for behavioural disturbances in dementia.

Authors:  K A Jellinger
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.

Authors:  G L Corona; M L Cucchi; P Frattini; G Santagostino; S Schinelli; A Romani; A Pola; F Zerbi; F Savoldi
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

6.  Nucleus raphe dorsalis in parkinsonism-dementia complex of Guam.

Authors:  T Yamamoto; A Hirano
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

Review 7.  Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment.

Authors:  C G Gottfries
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

Authors:  K L Goa; A Fitton
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

9.  Amyloid-P-component-like immunoreactivity in beta/A4-immunoreactive deposits in Alzheimer-type dementia brains.

Authors:  M Kimura; H Arai; T Takahashi; N Iwamoto
Journal:  J Neurol       Date:  1994-01       Impact factor: 4.849

10.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains.

Authors:  Adarsh M Kumar; J B Fernandez; Elyse J Singer; Deborah Commins; Drenna Waldrop-Valverde; Raymond L Ownby; Mahendra Kumar
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.